Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Migraine

Treatments: Drug: MK-0974 5Mo5C; Drug: telcagepant potassium; Drug: MK-0974 12Mo5C

Study type: Interventional

Funder types: Industry

Identifiers

NCT01209741

0974-038

Details and patient eligibility

About

This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.

Enrollment: 48 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject is in good health
• Subject is a nonsmoker
• Subject is willing to comply with the study restrictions

Exclusion criteria

• Subject has a history of stroke, chronic seizures, or major neurological disorder
• Subject has a history of cancer
• Subject is a nursing mother
• Subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

48 participants in 3 patient groups

1

Active Comparator group

Description:

MK-0974 12MoRT

Treatment:

Drug: telcagepant potassium

2

Active Comparator group

Description:

MK-0974 5Mo5C

Treatment:

Drug: MK-0974 5Mo5C

3

Active Comparator group

Description:

MK-0974 12Mo5C

Treatment:

Drug: MK-0974 12Mo5C